Tandem Diabetes Care Future Growth

Future criteria checks 1/6

Tandem Diabetes Care is forecast to grow earnings and revenue by 64.9% and 9.6% per annum respectively. EPS is expected to grow by 65.5% per annum. Return on equity is forecast to be -8.3% in 3 years.

Key information

64.9%

Earnings growth rate

65.5%

EPS growth rate

Medical Equipment earnings growth	16.1%
Revenue growth rate	9.6%
Future return on equity	-8.3%
Analyst coverage	Good
Last updated	30 Apr 2024

Recent future growth updates

Recent updates

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Mar 26

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Mar 08

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Feb 22

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Jan 14

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Dec 27

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Nov 12

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Oct 06

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

May 06

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Jan 04

Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?

Oct 15

Tandem Diabetes Care: Overpriced, Underdelivering

Sep 22

An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued

Sep 10

Tandem Diabetes stock falls 10% on disappointing Q2 result

Aug 03

Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed

Jul 21

Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings

Jul 08

Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital

Jun 20

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 43% Above Its Share Price

May 30

Here's Why Tandem Diabetes Care (NASDAQ:TNDM) Can Manage Its Debt Responsibly

Apr 17

Tandem Diabetes Care: Medical Instruments And Supplies Spell Market Success

Apr 01

Earnings and Revenue Growth Forecasts

NasdaqGM:TNDM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,028	-42	63	103	9
12/31/2025	937	-68	13	73	14
12/31/2024	845	-109	-24	48	15
12/31/2023	748	-223	-83	-32	N/A
9/30/2023	771	-208	-49	-19	N/A
6/30/2023	790	-224	-41	5	N/A
3/31/2023	795	-204	-33	18	N/A
12/31/2022	801	-95	8	50	N/A
9/30/2022	791	-68	21	64	N/A
6/30/2022	766	-13	50	74	N/A
3/31/2022	738	6	74	96	N/A
12/31/2021	703	16	88	111	N/A
9/30/2021	661	22	85	107	N/A
6/30/2021	605	7	62	87	N/A
3/31/2021	542	-25	45	74	N/A
12/31/2020	499	-34	-8	25	N/A
9/30/2020	439	-49	-6	29	N/A
6/30/2020	410	-42	5	37	N/A
3/31/2020	394	-17	1	25	N/A
12/31/2019	362	-25	22	42	N/A
9/30/2019	330	-24	23	37	N/A
6/30/2019	282	-55	0	10	N/A
3/31/2019	223	-113	-4	0	N/A
12/31/2018	184	-123	-11	-8	N/A
9/30/2018	148	-138	-38	-34	N/A
6/30/2018	129	-119	-52	-50	N/A
3/31/2018	116	-82	-61	-58	N/A
12/31/2017	108	-73	-72	-66	N/A
9/30/2017	96	-76	N/A	-68	N/A
6/30/2017	82	-90	N/A	-67	N/A
3/31/2017	83	-87	N/A	-66	N/A
12/31/2016	84	-83	N/A	-61	N/A
9/30/2016	84	-81	N/A	-58	N/A
6/30/2016	88	-70	N/A	-54	N/A
3/31/2016	81	-72	N/A	-59	N/A
12/31/2015	73	-72	N/A	-59	N/A
9/30/2015	62	-79	N/A	-62	N/A
6/30/2015	59	-79	N/A	-61	N/A
3/31/2015	54	-79	N/A	-60	N/A
12/31/2014	50	-80	N/A	-61	N/A
9/30/2014	42	-85	N/A	-61	N/A
6/30/2014	36	-78	N/A	-58	N/A
3/31/2014	32	-74	N/A	-56	N/A
12/31/2013	29	-63	N/A	-48	N/A
9/30/2013	21	-48	N/A	-45	N/A
6/30/2013	13	-43	N/A	-43	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TNDM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TNDM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TNDM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TNDM's revenue (9.6% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: TNDM's revenue (9.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TNDM is forecast to be unprofitable in 3 years.

Tandem Diabetes Care Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target increased by 7.8% to US$37.36

Consensus EPS estimates fall by 31%

Price target increased by 10.0% to US$31.67

Price target decreased by 26% to US$29.73

Price target decreased by 7.3% to US$37.80

Price target decreased by 8.8% to US$46.07

Recent updates

Price target increased by 7.8% to US$37.36

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

At US$30.10, Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Worth Looking At Closely?

Even With A 27% Surge, Cautious Investors Are Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

Consensus EPS estimates fall by 31%

Now 21% undervalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Price target increased by 10.0% to US$31.67

Now 23% undervalued

Estimating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stock Rockets 63% But Many Are Still Ignoring The Company

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Is It Too Late To Consider Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM)?

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 26% to US$29.73

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Price target decreased by 7.3% to US$37.80

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Intrinsic Value Is Potentially 53% Above Its Share Price

Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Now 23% undervalued after recent price drop

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Should You Think About Buying Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Now?

Price target decreased by 8.8% to US$46.07

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt Sensibly?

Independent Director recently bought US$295k worth of stock

Executive VP recently bought US$99k worth of stock

Consensus EPS estimates fall by 127%

Cautious Investors Not Rewarding Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) Performance Completely

First quarter 2023 earnings: EPS misses analyst expectations

Executive VP & COO notifies of intention to sell stock

Price target decreased by 8.1% to US$54.38

Full year 2022 earnings: EPS misses analyst expectations

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .

Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way?

Executive VP & COO notifies of intention to sell stock

Consensus forecasts updated

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

High number of new directors

Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 41% undervalued after recent price drop

Is Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Potentially Undervalued?

Tandem Diabetes Care, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Tandem Diabetes Care: Overpriced, Underdelivering

An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 50% Undervalued

Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:Connect Mobile App

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$100

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

Tandem Diabetes stock falls 10% on disappointing Q2 result

High number of new directors

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) acquired Capillary Biomedical, Inc.

Tandem Diabetes Care acquires Capillary Biomedical; terms undisclosed

Tandem Diabetes Care, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Tandem Diabetes Care: Strong Financials And Revenue, Overpenalized For Missed Earnings

High number of new directors

Tandem Diabetes Care Reports the Appointments of Myoung Cha and Joao Malagueira as Independent Members of Its Board of Directors, as of June 15, 2022

Tandem Diabetes Care (NASDAQ:TNDM) Is Looking To Continue Growing Its Returns On Capital